Sarcoidosis Pipeline Insights: Key Companies,Therapies, and Market Trends

DelveInsight's "Sarcoidosis Pipeline Insights 2026" Report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Sarcoidosis pipeline landscape. It covers the Sarcoidosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcoidosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Sarcoidosis Pipeline Report
• In September 2025, Shares of aTyr Pharma dropped by more than 80% after its Phase III clinical trial in pulmonary sarcoidosis did not achieve its primary endpoint. In the EFZO-FIT trial, Efzofitimod failed to demonstrate an improvement in mean daily oral corticosteroid (OCS) dose at Week 48. Patients receiving 5.0 mg/kg efzofitimod experienced an average OCS dose reduction of 2.79 mg, compared with a 3.52 mg reduction observed in the placebo group.
• In May 2025, Prednisone was commonly recommended as the first-line therapy for pulmonary sarcoidosis, although its use is often associated with several undesirable side effects. New findings presented at ATS 2025 suggest that Methotrexate may serve as an effective alternative. Researchers reported that methotrexate demonstrated comparable disease control to prednisone while potentially offering a lower risk of side effects.
• In March 2025, aTyr Pharma announced a fourth favorable Data Safety Monitoring Board (DSMB) assessment for its Phase III EFZO-FIT trial evaluating efzofitimod in pulmonary sarcoidosis. The DSMB found no safety issues and advised that the study proceed as planned, with topline data anticipated in the third quarter of 2025.
• In March 2025, Xentria, Inc. announced that enrollment has been completed for its Phase Ia/IIb XTMAB16 clinical trial in pulmonary sarcoidosis, with 39 patients recruited across four countries. The randomized, placebo-controlled, dose-ranging study exceeded its original enrollment goals.
• DelveInsight's Sarcoidosis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Sarcoidosis treatment.
• The leading Sarcoidosis Companies such as RELIEF THERAPEUTICS Holding SA , aTyr Pharma , Pfizer , United Therapeutics Corporation , Xentria, Inc. , Kyorin Pharmaceutical Co., Ltd, Novartis , Kinevant Sciences GmbH, Foresee Pharmaceuticals , AI Therapeutics, Molecure , and others.
• Promising Sarcoidosis Pipeline Therapies such as Efzofitimod, RLF-100, Abrocitinib, Inhaled Treprostinil, XTMAB-16, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Sarcoidosis Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Sarcoidosis Pipeline Report also highlights the unmet needs with respect to Sarcoidosis.

Sarcoidosis Overview
The multisystem illness sarcoidosis, whose cause is uncertain, is typified by non-caseating granulomas in the organs. This disease primarily affects young individuals and is characterized by bilateral hilar lymphadenopathy and reticular opacities in the lungs.

Sarcoidosis Emerging Drugs Profile

Efzofitimod: aTyr Pharma
Efzofitimod is an investigational therapeutic candidate developed by aTyr Pharma for the treatment of pulmonary sarcoidosis. The drug is currently in Phase III stage of clinical trial evaluation to treat Sarcoidosis.

RLF-100: Relief Therapeutics
RLF-100 is an investigational therapeutic candidate developed by Relief Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

Abrocitinib: Pfizer
Abrocitinib is an investigational therapeutic candidate developed by Pfizer for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

Inhaled Treprostinil: United Therapeutics
Inhaled Treprostinil is an investigational therapeutic candidate developed by United Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

XTMAB-16: Xentria, Inc.
XTMAB-16 is an investigational therapeutic candidate developed by Xentria, Inc. for the treatment of pulmonary sarcoidosis. The drug is currently in Phase Ia/IIb clinical trial evaluation to treat Sarcoidosis.

CMK389: Novartis
CMK389 is an investigational therapeutic candidate developed by Novartis for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

Namilumab: Kinevant Sciences GmbH
Namilumab is an investigational therapeutic candidate developed by Kinevant Sciences GmbH for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

FP-020: Foresee Pharmaceuticals
FP-020 is an investigational therapeutic candidate developed by Foresee Pharmaceuticals for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

LAM001: AI Therapeutics
LAM001 is an investigational therapeutic candidate developed by AI Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

OATD-01: Molecure
OATD-01 is an investigational therapeutic candidate developed by Molecure for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

The Sarcoidosis Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
• Sarcoidosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.

Explore groundbreaking therapies and clinical trials in the Sarcoidosis Pipeline @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Sarcoidosis Companies
Relief Therapeutics, aTyr Pharma, Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, and others.

Sarcoidosis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous

Sarcoidosis Products have been categorized under various Molecule types such as:
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Sarcoidosis Pipeline Report
• Coverage- Global
• Sarcoidosis Companies- RELIEF THERAPEUTICS Holding SA , aTyr Pharma , Pfizer , United Therapeutics Corporation , Xentria, Inc. , Kyorin Pharmaceutical Co., Ltd, Novartis , Kinevant Sciences GmbH, Foresee Pharmaceuticals , AI Therapeutics, Molecure , and others.
• Sarcoidosis Pipeline Therapies- Efzofitimod, RLF-100, Abrocitinib, Inhaled Treprostinil, XTMAB-16, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.
• Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Sarcoidosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Introduction
2. Executive Summary
3. Sarcoidosis: Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Sarcoidosis - DelveInsight's Analytical Perspective
8. Late Stage Products (Phase III)
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical Stage Products
12. Inactive Products
13. Sarcoidosis Key Companies
14. Sarcoidosis Key Products
15. Sarcoidosis - Unmet Needs
16. Sarcoidosis - Market Drivers and Barriers
17. Sarcoidosis - Future Perspectives and Conclusion
18. Sarcoidosis Analyst Views
19. Appendix

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.